## NSAIDs in Primary Dysmenorrhea: Mechanism of Action ### Cyclooxygenase Inhibition **Key Point:** NSAIDs exert their therapeutic effect by inhibiting cyclooxygenase (COX) enzymes, which catalyze the first committed step in prostaglandin synthesis. This reduces endometrial PGF2α production, thereby alleviating dysmenorrhea. ### Biochemical Pathway ```mermaid flowchart LR A[Arachidonic acid] -->|COX-1/COX-2| B[PGH2] B -->|PGF synthase| C[PGF2α] C -->|FP receptor| D[Myometrial contraction] E[NSAID] -.->|inhibits| A NSAID -->|blocks| B NSAID -.->|reduces| C C -.->|decreased| D style NSAID fill:#ff6b6b style D fill:#4ecdc4 ``` ### Clinical Efficacy 1. **Symptom Relief**: NSAIDs reduce dysmenorrhea severity by 60–90% when taken prophylactically (starting 1–2 days before menses or at symptom onset). 2. **Timing**: Prophylactic use (before pain onset) is more effective than reactive use, as it prevents prostaglandin accumulation. 3. **Commonly Used Agents**: Ibuprofen (400–600 mg TID), naproxen (250–500 mg BID), mefenamic acid (500 mg TID). **High-Yield:** Mefenamic acid is particularly effective because it not only inhibits COX but also acts as a non-competitive antagonist of prostaglandin receptors, providing dual inhibition. ### Why This Mechanism Is Superior **Clinical Pearl:** NSAIDs address the root cause (excess prostaglandin production) rather than treating symptoms downstream. This is why they are first-line therapy and why they work best when started prophylactically. ### Why Other Options Are Incorrect | Mechanism | Reality in Dysmenorrhea | |---|---| | **Calcium channel blockade** | Nifedipine has been studied but is less effective than NSAIDs; not first-line | | **Oxytocin antagonism** | Oxytocin plays a minor role; antagonists are not standard treatment | | **LH suppression** | Hormonal contraceptives suppress LH and are second-line; NSAIDs do not work via this mechanism | [cite:Berek & Novak 16e Ch 12; Harrison 21e Ch 382]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.